Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Extends Suspension of Activities for Takeda as It Awaits Ruling of Administrative Authority on Blopress Scandal
May 29, 2015
- Doctors Need to Be More Cost-Conscious When Prescribing: Dr Imamura of JMA
May 29, 2015
- FPMAJ, JPMA, and JGA Call for “Balanced” Approach to Control Drug Expenditure in Joint Declaration
May 28, 2015
- Generic Makers Need More Time to Meet Higher Target: JGA Leader
May 27, 2015
- 3 Companies Received Guidance, 2 Received Warnings in FY2014 due to Fair Competition Code Violations: Maker’s FTC
May 27, 2015
- JPMA Chief Fires at Proposed 80-90% Generic Share Target
May 27, 2015
- JPMA Official Praises Sakigake System as “Ground-Breaking,” Expresses Concern Over Impact of Compassionate Use System
May 12, 2015
- “Stable Supply System” Key for Adopting Generics at Insurance Pharmacies: JGA Survey
May 11, 2015
- JPMA Preparing “Action Guidelines” to Ensure Greater Transparency
April 24, 2015
- Expert Warns against Research-Driven Makers’ Foray into Indian Market
April 22, 2015
- JPMA to Step Up Calls for Biowaivers Using IVIVC
April 21, 2015
- MHLW to Inquire with Drug Makers about Payments to PAFSC Members
April 17, 2015
- Japan Drug Costs to Remain Flat thru 2025, No Annual Price Cuts Necessary: EFPIA
April 15, 2015
- APAC Approves “Good Submission Practice” Guidelines Aimed at Reducing Time to Approval in Asia
April 13, 2015
- JPA Vice President Disagrees with Exclusion of OTC-Like Drugs from Insurance Coverage
April 13, 2015
- JPMA to Closely Watch Clinical Research Bill to Decide Whether to Review All Ads
April 6, 2015
- October-December Generic Share Down 1.3 Points from Prior Qtr: JGA
March 27, 2015
- 15 Drug Makers to Jointly Purchase 150,000 Compounds for Compound Libraries Over 5-Year Period Starting in FY2015
March 27, 2015
- 1st Generation Poultices “Just One Example” for Proposal to Scrap Health Coverage for OTC-Like Drugs: Shirakawa
March 26, 2015
- Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
March 26, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…